bioRASI completes acquisition of Sponsors Clinical Research Group
bioRASI, a global full service CRO, has acquired Sponsors Clinical Research Group (SCRG), a Ukraine-based regulatory and clinical CRO. SCRG was established in 2004 and has been conducting clinical studies in an extensive range of therapeutic areas including cardiology, neurology, oncology, endocrinology and pulmonology.
"We have been working with SCRG for over a year and have been impressed with the superior expertise of its staff, so it was only natural to consider a more integrated structure," said Dr. Boris Reznik, chairman of bioRASI. "This acquisition enhances bioRASI's global infrastructure focused on delivering optimized clinical development for our sponsors who are under increasing pressure to accelerate drug development timelines while minimizing costs."
The acquisition of SCRG addresses the ever-increasing demand for optimizing global clinical trials and builds upon bioRASI's presence throughout Eastern Europe.
"While SCRG has been working for many global sponsors and CROs, we have never experienced the powers of project management comparable to that of bioRASI," said Dr. Veklych, SCRG's executive director. "An integrated set of tools embodied in the bioRASI Process Infrastructure (BPI) greatly enhances optimized project delivery capabilities. We are excited about being a part of bioRASI's winning team."